{"id":"denosumab-reduced-dosing","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1237023","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Denosumab binds to receptor activator of nuclear factor kappa-B ligand (RANKL), a key mediator of osteoclast differentiation and activation. By blocking RANKL signaling, it reduces bone turnover and increases bone mineral density. The reduced dosing regimen aims to maintain efficacy while minimizing systemic exposure and potential adverse effects.","oneSentence":"Denosumab is a monoclonal antibody that inhibits RANKL, preventing osteoclast formation and bone resorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:32.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of skeletal-related events in patients with bone metastases from solid tumors"},{"name":"Treatment of giant cell tumor of bone"}]},"trialDetails":[{"nctId":"NCT02051218","phase":"PHASE3","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2014-07-16","conditions":"Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases","enrollment":1380}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XGEVA®"],"phase":"phase_3","status":"active","brandName":"Denosumab (reduced dosing)","genericName":"Denosumab (reduced dosing)","companyName":"Swiss Cancer Institute","companyId":"swiss-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Denosumab is a tumor necrosis factor ligand superfamily member 11 inhibitor, classified as an antibody, which has been studied for the prevention of symptomatic skeletal events in conditions such as metastatic breast cancer, metastatic prostate cancer, and bone metastases. Clinical trials have compared the effectiveness of denosumab administered every 4 weeks versus every 12 weeks in these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}